COMMUNIQUÉS West-GlobeNewswire

New Data Shows Biodesix Blood Test Reliably Detects Additional Mutations in Patients with NSCLC
18/04/2018
Highly multiplexed ddPCR-based assay currently in use by biopharma partners BOULDER, Colo., April 18, 2018 (GLOBE NEWSWIRE) -- Biodesix ® , Inc. is presenting new data today demonstrating the ability of the company’s [...]
AXIM Biotech Files Patent Application on Product Formulation Comprised of Cannabinoids With Anti-Bacterial and Anti-Fungal Activities
18/04/2018
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc. (AXIM ® Biotech ), (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the European Patent Office (EPO) has [...]
Checkpoint Therapeutics Reports Preclinical Data on BET Inhibitor CK-103 at the American Association for Cancer Research Annual Meeting
18/04/2018
Data support the commencement of a first-in-human Phase 1 trial NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT ), a clinical-stage, immuno-oncology [...]
Mydx Announces 2017 Fiscal Year Results
18/04/2018
Gross Profit Margin Surged to 73% with Gross Profits Remaining Relatively Flat at ~$306K as MyDx Continues to Execute on its Long-Term Strategy SAN DIEGO, CA , April 18, 2018 (GLOBE NEWSWIRE) -- MyDx, Inc. ( OTC: MYDX [...]
TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Company’s BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting
18/04/2018
NEW YORK, April 18, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX ), today announced preclinical data for TG-1601, the Company’s novel BET inhibitor at the American Association for Cancer Research (AACR) [...]
BioPorto appoints Ole Larsen as CFO
18/04/2018
April 18, 2018 Announcement no. 9 Ole Larsen, Executive Vice President & CFO of Bavarian Nordic, will as of June 1, 2018, join BioPorto as the new Chief Financial Officer. In 2008, Ole Larsen joined Bavarian Nordic [...]
CV Sciences, Inc. Announces Silver Level Sponsorship of the 15th Annual Nutrition and Health Conference in Boston, Massachusetts - April 29-May 2, 2018
18/04/2018
Company Continues its Expansion into the Healthcare Professional Market through One-on-One Education, Exclusive Product Offerings and Enhanced Practitioner Support. LAS VEGAS, April 18, 2018 (GLOBE NEWSWIRE) -- CV [...]
Marrone Bio Innovations, Inc. Announces Pricing of Its Common Stock Offering
18/04/2018
DAVIS, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (NASDAQ: MBII ) (or "the Company"), a leading provider of bio-based pest management and plant health products for the agriculture, turf and [...]
Teladoc to Announce First Quarter 2018 Financial Results
18/04/2018
PURCHASE, NY, April 18, 2018 (GLOBE NEWSWIRE) -- Teladoc , Inc. (NYSE: TDOC ), the world’s largest and most trusted provider of virtual care delivery services, announced today that it will release first quarter 2018 [...]
Origin Successfully Achieves Phase IIb GENESIS Trial Objectives Ahead of Schedule and Announces Early Termination of Study
18/04/2018
PRINCETON, N.J., April 18, 2018 (GLOBE NEWSWIRE) -- Origin, Inc., a Phase IIb clinical-stage biotechnology company, today announced that the US Food and Drug Administration has approved its request to conclude patient [...]
Alder BioPharmaceuticals® to Present New Phase 3 Migraine Prevention Data for Eptinezumab at the 70th Annual American Academy of Neurology Meeting
18/04/2018
PROMISE 2 Phase 3 study selected for Emerging Science clinical trials plenary presentation session on April 24, 2018 BOTHELL, Wash., April 18, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR ), a [...]
Interpace Diagnostics Enters Agreement with One of the Largest, Integrated Health Systems in the US
18/04/2018
Agreement with BJC Healthcare Covers Both of the Company’s Thyroid Tests PARSIPPANY, N.J., April 18, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG ) (“Interpace” or “the Company”), a fully [...]
Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors
18/04/2018
Experienced Life Sciences Executive to Serve as Member of Histogenics Board of Directors WALTHAM, Mass., April 18, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX ), a leader in the [...]
INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device
18/04/2018
PHOENIX, April 18, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced [...]
Ceapro Inc. Announces Important Collaboration with Prestigious Montreal Heart Institute
18/04/2018
- Beta-glucan project expected to be Ceapro’s first clinical project led by MHI’s Montreal Health Innovations Coordinating Center (MHICC) - EDMONTON, ALBERTA, April 18, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO [...]
Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
18/04/2018
NORCROSS, Ga., April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’ [...]
Retrotope Announces Peer-Reviewed Publication of Positive Phase 1b/2a Findings for RT001 in Friedreich’s Ataxia
18/04/2018
Protocol for Pivotal Clinical Trial Has Been Submitted to the US FDA LOS ALTOS, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Retrotope announced today peer-reviewed publication of positive Phase 1b/2a trial results for [...]
Trayt Unveils Application to Improve Diagnosis, Treatment and Quality of Life for Patients with Autism, ADHD and Neurodevelopmental Disorders
18/04/2018
Big Data and Analytics Platform Measures Efficacy of Interventions and Engages the Entire System of Care REDWOOD CITY, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Trayt , the data analytics company with a platform for [...]
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
18/04/2018
Grant Expected to Fund Development of OPNT003 to NDA Ready Stage SANTA MONICA, Calif., April 18, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT ), a specialty pharmaceutical company [...]

Pages